BA
ORMP icon

Bivin & Associates’s Oramed Pharmaceuticals ORMP Stock Holding History

Bivin & Associates’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$4K Hold
800
– – ﹤0.01% 198
2022
Q1 		$7K Buy
800
+100
+14% +$1.02K 0.01% 192
2021
Q4 		$10K Buy
+700
New +$14.6K 0.01% 186

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bivin & Associates's ORMP Position: Q2 2022 in Review

Bivin & Associates held its Oramed Pharmaceuticals (ORMP) position steady in Q2 2022 at 800 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #198.

Bivin & Associates first reported a position in ORMP in Q4 2021 and has held it in 3 quarters since. The position peaked at $10K in Q4 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • Bivin & Associates held 800 shares of Oramed Pharmaceuticals worth $4K as of Q2 2022.
  • Bivin & Associates left its Oramed Pharmaceuticals share count unchanged in Q2 2022.
  • Oramed Pharmaceuticals made up ﹤0.01% of Bivin & Associates's portfolio in Q2 2022, its #198 holding.
  • Bivin & Associates first reported a position in Oramed Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
  • Bivin & Associates's Oramed Pharmaceuticals position peaked at $10K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on Bivin & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.